Prochlorperazine (BioDeep_00000002062)

human metabolite blood metabolite Chemicals and Drugs

代谢物信息卡片

2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine

化学式: C20H24ClN3S (373.1379)
中文名称: 奋乃静
谱图信息: 最多检出来源 Homo sapiens(blood) 42.81%

分子结构信息

SMILES: CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
InChI: InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3

描述信息

Prochlorperazine is only found in individuals that have used or taken this drug. It is a phenothiazine antipsychotic used principally in the treatment of nausea; vomiting; and vertigo. It is more likely than chlorpromazine to cause extrapyramidal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)The mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its antidopaminergic effects. Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. Prochlorperazine also has anti-emetic effects, which can be attributed to dopamine blockade in the chemoreceptor trigger zone. Prochlorperazine also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha(1)-adrenergic receptors resulting in sedation, muscle relaxation, and hypotension.
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists
C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent > C740 - Phenothiazine
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
D005765 - Gastrointestinal Agents > D000932 - Antiemetics

同义名列表

31 个代谢物同义名

2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; N-(gamma-(4-Methylpiperazinyl-1)propyl)-3-chlorophenothiazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; N-(Γ-(4-methylpiperazinyl-1)propyl)-3-chlorophenothiazine; N-(g-(4-Methylpiperazinyl-1)propyl)-3-chlorophenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Salt, prochlorperazine edisylate; Edisylate salt, prochlorperazine; Prochlorperazine edisylate salt; Edisylate, prochlorperazine; Prochlorperazine edisylate; Maleate, prochlorperazine; Prochlorperazine maleate; Prochlorpermazine; Prochlorpromazine; Prochlorperazinum; Prochloroperazine; Prochlorpemazine; prochlorperazine; Prochlorperazin; Proclorperazina; Proclorperazine; Procloperazine; Chlormeprazine; Chlorperazine; Compazine; Compro; Prochlorperazine

数据库引用编号

18 个数据库交叉引用编号

ChEBI: CHEBI:8435
KEGG: C07403
KEGGdrug: D00493
PubChem: 4917
HMDB: HMDB0014577
Metlin: METLIN2111
DrugBank: DB00433
ChEMBL: CHEMBL728
Wikipedia: Prochlorperazine
MeSH: Prochlorperazine
chemspider: 4748
CAS: 58-38-8
PMhub: MS000001763
PubChem: 9607
PDB-CCD: P77
NIKKAJI: J1.386B
RefMet: Prochlorperazine
KNApSAcK: 8435

分类词条

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

9606 - Homo sapiens: -

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位		关联基因列表
Cytoplasm	6	ABCB1, CYP2D6, DNM2, EGFR, PRL, TYR
Peripheral membrane protein	2	CYP1B1, DNM2
Endosome membrane	1	EGFR
Endoplasmic reticulum membrane	4	CYP1B1, CYP2D6, EGFR, RNF43
Nucleus	4	EGFR, MPO, PRL, USP27X
cytosol	2	DNM2, USP27X
dendrite	3	DRD2, HTR1D, OPRM1
centrosome	1	DNM2
nucleoplasm	2	MPO, PRL
RNA polymerase II transcription regulator complex	1	PRL
Cell membrane	9	ABCB1, DRD2, EGFR, HTR1D, HTR3A, KCNH2, OPRM1, RNF43, SLC12A5
Cleavage furrow	1	HTR3A
ruffle membrane	1	EGFR
Cell projection, axon	1	OPRM1
Early endosome membrane	1	EGFR
Multi-pass membrane protein	8	ABCB1, CACNA1I, DRD2, HTR1D, HTR3A, KCNH2, OPRM1, SLC12A5
Golgi apparatus membrane	1	DRD2
Synapse	5	DNM2, DRD2, HTR1D, HTR3A, OPRM1
cell junction	2	DNM2, EGFR
cell surface	3	ABCB1, EGFR, KCNH2
glutamatergic synapse	4	C1QL3, DRD2, EGFR, SLC12A5
Golgi apparatus	2	DNM2, OPRM1
Golgi membrane	4	DNM2, DRD2, EGFR, INS
neuronal cell body	1	SLC12A5
postsynapse	1	HTR3A
presynaptic membrane	1	DRD2
Cytoplasm, cytosol	1	USP27X
Lysosome	2	MPO, TYR
Presynapse	1	DNM2
acrosomal vesicle	1	DRD2
endosome	3	DNM2, EGFR, OPRM1
plasma membrane	12	ABCB1, CACNA1I, DNM2, DRD2, EGFR, F2, HTR1D, HTR3A, KCNH2, OPRM1, RNF43, SLC12A5
synaptic vesicle membrane	1	DRD2
Membrane	9	ABCB1, CACNA1I, CYP1B1, CYP2D6, EGFR, HTR3A, KCNH2, OPRM1, SLC12A5
apical plasma membrane	2	ABCB1, EGFR
axon	2	DRD2, OPRM1
basolateral plasma membrane	1	EGFR
extracellular exosome	4	ABCB1, DNM2, F2, MPO
endoplasmic reticulum	2	CYP2D6, OPRM1
extracellular space	5	EGFR, F2, INS, MPO, PRL
perinuclear region of cytoplasm	3	EGFR, KCNH2, TYR
mitochondrion	2	CYP1B1, CYP2D6
protein-containing complex	1	EGFR
intracellular membrane-bounded organelle	4	CYP1B1, CYP2D6, MPO, TYR
Microsome membrane	2	CYP1B1, CYP2D6
postsynaptic density	1	DNM2
Single-pass type I membrane protein	3	EGFR, RNF43, TYR
Secreted	4	C1QL3, F2, INS, PRL
extracellular region	4	F2, INS, MPO, PRL
Single-pass membrane protein	1	CYP2D6
hippocampal mossy fiber to CA3 synapse	1	C1QL3
ciliary membrane	1	DRD2
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome	1	DNM2
nuclear membrane	1	EGFR
dendritic spine	1	DRD2
perikaryon	3	DRD2, OPRM1, SLC12A5
Melanosome membrane	1	TYR
midbody	1	DNM2
Membrane, clathrin-coated pit	1	DNM2
clathrin-coated pit	1	DNM2
Golgi-associated vesicle	1	TYR
recycling endosome	1	DNM2
postsynaptic membrane	3	DNM2, DRD2, HTR3A
Apical cell membrane	1	ABCB1
Membrane raft	1	EGFR
Cytoplasm, cytoskeleton	1	DNM2
focal adhesion	2	DNM2, EGFR
microtubule	1	DNM2
GABA-ergic synapse	1	DRD2
collagen trimer	1	C1QL3
intracellular vesicle	1	EGFR
collagen-containing extracellular matrix	1	F2
secretory granule	1	MPO
lateral plasma membrane	1	DRD2
Postsynaptic cell membrane	1	HTR3A
receptor complex	1	EGFR
neuron projection	4	DNM2, HTR3A, OPRM1, SLC12A5
cilium	1	DRD2
chromatin	1	PRL
Cytoplasmic vesicle, phagosome membrane	1	DNM2
Cell projection, phagocytic cup	1	DNM2
phagocytic cup	1	DNM2
phagocytic vesicle membrane	1	DNM2
cell periphery	1	SLC12A5
Cell projection, podosome	1	DNM2
podosome	1	DNM2
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole	1	DNM2
centriole	1	DNM2
blood microparticle	1	F2
non-motile cilium	1	DRD2
serotonin-activated cation-selective channel complex	1	HTR3A
transmembrane transporter complex	1	HTR3A
sperm flagellum	1	DRD2
nuclear envelope	1	RNF43
endosome lumen	2	INS, PRL
monoatomic ion channel complex	1	KCNH2
Cell projection, dendrite	2	OPRM1, SLC12A5
Melanosome	1	TYR
basal plasma membrane	1	EGFR
azurophil granule	1	MPO
clathrin-coated vesicle	1	DNM2
inward rectifier potassium channel complex	1	KCNH2
synaptic membrane	1	EGFR
voltage-gated potassium channel complex	1	KCNH2
secretory granule lumen	1	INS
Golgi lumen	2	F2, INS
endoplasmic reticulum lumen	2	F2, INS
axon terminus	1	DRD2
voltage-gated calcium channel complex	1	CACNA1I
endocytic vesicle membrane	1	DNM2
Cytoplasmic vesicle, clathrin-coated vesicle	1	DNM2
endocytic vesicle	1	DRD2
transport vesicle	1	INS
azurophil granule lumen	1	MPO
Endoplasmic reticulum-Golgi intermediate compartment membrane	1	INS
clathrin-coated endocytic vesicle membrane	1	EGFR
phagocytic vesicle lumen	1	MPO
uropod	1	DNM2
Synapse, synaptosome	1	DNM2
synaptic cleft	1	C1QL3
external side of apical plasma membrane	1	ABCB1
postsynaptic specialization membrane	1	SLC12A5
dopaminergic synapse	1	DRD2
dendrite membrane	1	SLC12A5
Cell projection, uropodium	1	DNM2
multivesicular body, internal vesicle lumen	1	EGFR
Shc-EGFR complex	1	EGFR
G protein-coupled receptor complex	1	DRD2
[Isoform 12]: Cytoplasm	1	OPRM1

文献列表

Kirti Sad, Palak Parashar, Pragya Tripathi, Hungharla Hungyo, Ramesh Sistla, Ravi Soni, Vibha Tandon. Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. Free radical biology & medicine. 2021 12; 177(?):299-312. doi: 10.1016/j.freeradbiomed.2021.11.001. [PMID: 34742922]
Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
C S Kow, S S Hasan. Prochlorperazine for nausea and vomiting accompanied COVID-19. Journal of gastroenterology and hepatology. 2021 Feb; 36(2):524-525. doi: 10.1111/jgh.15301. [PMID: 33068035]
Michał Otręba, Leon Kośmider, Anna Rzepecka-Stojko. Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. A review. European journal of pharmacology. 2020 Nov; 887(?):173553. doi: 10.1016/j.ejphar.2020.173553. [PMID: 32949606]
Masaki Tashiro, Takafumi Naito, Yoshiyuki Kagawa, Junichi Kawakami. Influence of cytochrome P450 genotype on the plasma disposition of prochlorperazine metabolites and their relationships with clinical responses in cancer patients. Annals of clinical biochemistry. 2018 May; 55(3):385-393. doi: 10.1177/0004563217731432. [PMID: 28853295]
M Otręba, E Buszman. Perphenazine and prochlorperazine induce concentration-dependent loss in human glioblastoma cells viability. Die Pharmazie. 2018 Jan; 73(1):19-21. doi: 10.1691/ph.2018.7806. [PMID: 29441946]
Masaki Tashiro, Takafumi Naito, Kazunori Ohnishi, Yoshiyuki Kagawa, Junichi Kawakami. Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients. Clinica chimica acta; international journal of clinical chemistry. 2014 Feb; 429(?):175-80. doi: 10.1016/j.cca.2013.12.011. [PMID: 24360851]
Ana M Chamoun-Emanuelli, Eve-Isabelle Pecheur, Rudo L Simeon, Da Huang, Paul S Cremer, Zhilei Chen. Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrobial agents and chemotherapy. 2013 Jun; 57(6):2571-81. doi: 10.1128/aac.02593-12. [PMID: 23529728]
Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
Masaki Tashiro, Takafumi Naito, Yoshiyuki Kagawa, Junichi Kawakami. Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry. Biomedical chromatography : BMC. 2012 Jun; 26(6):754-60. doi: 10.1002/bmc.1725. [PMID: 21990013]
Ann R Holmes, Mikhail V Keniya, Irena Ivnitski-Steele, Brian C Monk, Erwin Lamping, Larry A Sklar, Richard D Cannon. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Antimicrobial agents and chemotherapy. 2012 Mar; 56(3):1508-15. doi: 10.1128/aac.05706-11. [PMID: 22203607]
J N Cheng, A Lee, J Jannes, R J Heddle, S A Koblar. A patient with anaphylaxis after alteplase infusion. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2012 Feb; 19(2):314-5. doi: 10.1016/j.jocn.2011.07.018. [PMID: 22099072]
Shuhao Yu, Zhizhong Guo, Yan Guan, Yi-Yu Lu, Pei Hao, Yixue Li, Shi-Bing Su. Combining ZHENG Theory and High-Throughput Expression Data to Predict New Effects of Chinese Herbal Formulae. Evidence-based complementary and alternative medicine : eCAM. 2012; 2012(?):986427. doi: 10.1155/2012/986427. [PMID: 22666299]
Megan E Musselman, Linda A Browning, Dennis Parker, Suprat Saely. Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome. The Annals of pharmacotherapy. 2011 Nov; 45(11):e61. doi: 10.1345/aph.1q325. [PMID: 21972252]
Iida Peltonen, Pekka T Männistö. Effects of diverse psychopharmacological substances on the activity of brain prolyl oligopeptidase. Basic & clinical pharmacology & toxicology. 2011 Jan; 108(1):46-54. doi: 10.1111/j.1742-7843.2010.00626.x. [PMID: 20825390]
Dominique P Germain. Fabry disease. Orphanet journal of rare diseases. 2010 Nov; 5(?):30. doi: 10.1186/1750-1172-5-30. [PMID: 21092187]
Till Krech, Margarethe Thiede, Ellen Hilgenberg, Reinhold Schäfer, Karsten Jürchott. Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations. BMC cancer. 2010 Jun; 10(?):287. doi: 10.1186/1471-2407-10-287. [PMID: 20546605]
Eduardo Costa Figueiredo, Gustavo Braga Sanvido, Marco Aurélio Zezzi Arruda, Marcos Nogueira Eberlin. Molecularly imprinted polymers as analyte sequesters and selective surfaces for easy ambient sonic-spray ionization. The Analyst. 2010 Apr; 135(4):726-30. doi: 10.1039/b923289c. [PMID: 20309446]
Miao Yan, Yun-Gui Zhu, Huan-De Li, Ben-Mei Chen, Ning Ma, Yan-Qing Lei, Yi-Ping Liu. Quantification of prochlorperazine maleate in human plasma by liquid chromatography-mass spectrometry: Application to a bioequivalence study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Oct; 877(27):3243-7. doi: 10.1016/j.jchromb.2009.07.038. [PMID: 19682959]
Kristy Dolan, Sara Montgomery, Bradley Buchheit, Louis Didone, Melanie Wellington, Damian J Krysan. Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrobial agents and chemotherapy. 2009 Aug; 53(8):3337-46. doi: 10.1128/aac.01564-08. [PMID: 19487443]
Marcin Kolaczkowski, Anna Kolaczkowska, Noboru Motohashi, Krystyna Michalak. New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. Antimicrobial agents and chemotherapy. 2009 Apr; 53(4):1516-27. doi: 10.1128/aac.00956-08. [PMID: 19188399]
M J Avram, D A Spyker, T K Henthorn, J V Cassella. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clinical pharmacology and therapeutics. 2009 Jan; 85(1):71-7. doi: 10.1038/clpt.2008.184. [PMID: 18830225]
M Cruz-Vera, R Lucena, S Cárdenas, M Valcárcel. Determination of phenothiazine derivatives in human urine by using ionic liquid-based dynamic liquid-phase microextraction coupled with liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Jan; 877(1-2):37-42. doi: 10.1016/j.jchromb.2008.11.017. [PMID: 19042163]
Ramadhan Oruch, Erlend Hodneland, Ian F Pryme, Holm Holmsen. Psychotropic drugs interfere with the tight coupling of polyphosphoinositide cycle metabolites in human platelets: a result of receptor-independent drug intercalation in the plasma membrane?. Biochimica et biophysica acta. 2008 Oct; 1778(10):2165-76. doi: 10.1016/j.bbamem.2008.04.007. [PMID: 18503745]
R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
Ian N Olver. Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Therapeutics and clinical risk management. 2008 Apr; 4(2):501-6. doi: 10.2147/tcrm.s2345. [PMID: 18728837]
Jie Cao, Shi-min Luo, Li-jian Liang, Wen-jie Hu. [Effect of branched-chain amino acid-rich parenteral nutrition on protein metabolism after partial hepatectomy in rats with liver cirrhosis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2007 Nov; 27(11):1721-3. doi: NULL. [PMID: 18024299]
Einosuke Tanaka, Takako Nakamura, Masaru Terada, Tatsuo Shinozuka, Chikako Hashimoto, Katsuyoshi Kurihara, Katsuya Honda. Simple and simultaneous determination for 12 phenothiazines in human serum by reversed-phase high-performance liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Jul; 854(1-2):116-20. doi: 10.1016/j.jchromb.2007.04.004. [PMID: 17459789]
Michael J Avram, Thomas K Henthorn, Daniel A Spyker, Tom C Krejcie, Peter M Lloyd, James V Cassella, Joshua D Rabinowitz. Recirculatory pharmacokinetic model of the uptake, distribution, and bioavailability of prochlorperazine administered as a thermally generated aerosol in a single breath to dogs. Drug metabolism and disposition: the biological fate of chemicals. 2007 Feb; 35(2):262-7. doi: 10.1124/dmd.106.010652. [PMID: 17079359]
Mayowa O Owolabi, Okechukwu S Ogah, Adesola Ogunniyi. Episodic vertigo resulting from vascular risk factors, cervical spondylosis and head rotation: Two case reports. Neuropsychiatric disease and treatment. 2007; 3(5):675-8. doi: ". [PMID: 19300597]
Anna Ferrari, Gustavo Savino, Daniela Gallesi, Diego Pinetti, Alfio Bertolini, Grazia Sances, Ciro Pio Rosario Coccia, Gabriella Pasciullo, Sheila Leone, Marianna Loi, Emilio Sternieri. Effect of overuse of the antimigraine combination of indomethacin, prochlorperazine and caffeine (IPC) on the disposition of its components in chronic headache patients. Pharmacological research. 2006 Aug; 54(2):142-9. doi: 10.1016/j.phrs.2006.03.022. [PMID: 16697657]
Hope E Uronis, David C Currow, Amy P Abernethy. Palliative management of refractory dyspnea in COPD. International journal of chronic obstructive pulmonary disease. 2006; 1(3):289-304. doi: 10.2147/copd.2006.1.3.289. [PMID: 18046866]
Andrew Finn, Jason Collins, Robert Voyksner, Celeste Lindley. Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route. Journal of clinical pharmacology. 2005 Dec; 45(12):1383-90. doi: 10.1177/0091270005281044. [PMID: 16291713]
Akemi Marumo, Takeshi Kumazawa, Xiao-Pen Lee, Koichiro Fujimaki, Ayako Kuriki, Chika Hasegawa, Keizo Sato, Hiroshi Seno, Osamu Suzuki. Analysis of phenothiazines in human body fluids using disk solid-phase extraction and liquid chromatography. Journal of AOAC International. 2005 Nov; 88(6):1655-60. doi: . [PMID: 16526447]
Li-jian Liang, Shi-min Luo, Wen-jie Hu. [Effects of amino acid solution and recombinant human growth hormone on growth hormone/insulin like growth factor-1 axis in rats with liver cirrhosis]. Zhonghua wai ke za zhi [Chinese journal of surgery]. 2005 Jun; 43(11):697-701. doi: NULL. [PMID: 16008955]
Yoshioki Satoh, Atsushi Sugiyama, Akira Takahara, Kentaro Ando, Kai Wang, Sachiko Honsho, Keitaro Hashimoto. The antipsychotic and antiemetic drug prochlorperazine delays the ventricular repolarization of the in situ canine heart. Journal of pharmacological sciences. 2005 Jan; 97(1):101-6. doi: 10.1254/jphs.fpj04038x. [PMID: 15655290]
Stacey L Berg, Alexander Aleksic, Leticia McGuffey, Robert Dauser, Jed Nuchtern, Bruce Bernacky, Susan M Blaney. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. Cancer chemotherapy and pharmacology. 2004 Aug; 54(2):127-30. doi: 10.1007/s00280-004-0787-0. [PMID: 15150671]
Ayse L Mindikoglu, Abhinandana Anantharaju, Grace G Hartman, Shilun D Li, Jaime Villanueva, David H Van Thiel. Prochlorperazine-induced cholestasis in a patient with alpha-1 antitrypsin deficiency. Hepato-gastroenterology. 2003 Sep; 50(53):1338-40. doi: NULL. [PMID: 14571732]
Aron D Mosnaim, Javier Puente, Rolando Saavedra, Seymour Diamond, Marion E Wolf. In vitro human plasma leucine(5)-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. Pharmacology. 2003 Jan; 67(1):6-13. doi: 10.1159/000066781. [PMID: 12444298]
Yasushi Mizuno, Keizo Sato, Toshiyuki Sano, Rina Kurihara, Takashi Kojima, Yoshinori Yamakawa, Akira Ishii, Yoshinao Katsumata. Identification and characterization of 17 phenothiazine compounds by capillary high-performance liquid chromatography/fast atom bombardment mass spectrometry. Legal medicine (Tokyo, Japan). 2002 Dec; 4(4):207-16. doi: 10.1016/s1344-6223(02)00051-2. [PMID: 12935655]
A Krishan, K S Sridhar, C Mou, W D Stein, E Lyubimov, Y P Hu, H Fernandez. Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Apr; 6(4):1508-17. doi: . [PMID: 10778983]
S Ginder, B Oatman, M Pollack. A prospective study of i.v. magnesium and i.v. prochlorperazine in the treatment of headaches. The Journal of emergency medicine. 2000 Apr; 18(3):311-5. doi: 10.1016/s0736-4679(99)00220-6. [PMID: 10729668]
J W Raschko, T W Synold, W Chow, P Coluzzi, V Hamasaki, L A Leong, K A Margolin, R J Morgan, S I Shibata, G Somlo, M L Tetef, Y Yen, A ter Veer, J H Doroshow. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. Cancer chemotherapy and pharmacology. 2000; 46(5):403-10. doi: 10.1007/s002800000142. [PMID: 11127945]
S Singh, D R Sharma, A Chaudhary. Evaluation of prochlorperazine buccal tablets (Bukatel) and metoclopramide oral tablets in the treatment of acute emesis. Journal of the Indian Medical Association. 1999 Aug; 97(8):346-7. doi: NULL. [PMID: 10643185]
C M Bond. Comparison of buccal and oral prochlorperazine in the treatment of dizziness associated with nausea and/or vomiting. Current medical research and opinion. 1998; 14(4):203-12. doi: 10.1185/03007999809113360. [PMID: 9891192]
C Mou, N Ganju, K S Sridhar, A Krishan. Simultaneous quantitation of plasma doxorubicin and prochlorperazine content by high-performance liquid chromatography. Journal of chromatography. B, Biomedical sciences and applications. 1997 Dec; 703(1-2):217-24. doi: 10.1016/s0378-4347(97)00414-3. [PMID: 9448079]
M S Webb, J J Wheeler, M B Bally, L D Mayer. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochimica et biophysica acta. 1995 Sep; 1238(2):147-55. doi: 10.1016/0005-2736(95)00121-i. [PMID: 7548129]
T Shimada, K Higashi, K Kimura, T Shido, K Tomita. Syndrome of inappropriate antidiuresis seen twice in eight years. Endocrine journal. 1995 Apr; 42(2):163-9. doi: 10.1507/endocrj.42.163. [PMID: 7627260]
C W Scarantino, R D Ornitz, L G Hoffman, R F Anderson. On the mechanism of radiation-induced emesis: the role of serotonin. International journal of radiation oncology, biology, physics. 1994 Nov; 30(4):825-30. doi: 10.1016/0360-3016(94)90356-5. [PMID: 7525517]
S S Hasan, A Joshi. Effect of prochlorperazine as a sensitizer of rat skin on radiation-induced AMP metabolism. La Radiologia medica. 1994 Jun; 87(6):837-46. doi: . [PMID: 7518933]
P A Phillips, L M Burrell, J Risvanis, J Stephenson, C I Johnston, A M Hutchins. Effects of anti-emetics on water excretion in humans. Clinical and experimental pharmacology & physiology. 1994 Jan; 21(1):59-62. doi: 10.1111/j.1440-1681.1994.tb02436.x. [PMID: 8156653]
K S Sridhar, A Krishan, T S Samy, R C Duncan, A Sauerteig, G V McPhee, M E Auguste, P W Benedetto. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. Cancer chemotherapy and pharmacology. 1994; 34(5):377-84. doi: 10.1007/bf00685561. [PMID: 8070004]
G Watt, A Na-Nakorn, D N Bateman, N Plubha, P Mothanaprakoon, M Edstein, H K Webster. Amplification of quinine cardiac effects by the resistance-reversing agent prochlorperazine in falciparum malaria. The American journal of tropical medicine and hygiene. 1993 Nov; 49(5):645-9. doi: 10.4269/ajtmh.1993.49.645. [PMID: 8250106]
K S Sridhar, A Krishan, T S Samy, A Sauerteig, L L Wellham, G McPhee, R C Duncan, S Y Anac, B Ardalan, P W Benedetto. Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. Cancer chemotherapy and pharmacology. 1993; 31(6):423-30. doi: 10.1007/bf00685030. [PMID: 8453681]
M C Nahata, C Ford, F B Ruymann. Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. Journal of clinical pharmacy and therapeutics. 1992 Apr; 17(2):121-3. doi: 10.1111/j.1365-2710.1992.tb01279.x. [PMID: 1583079]
A O Isah, M D Rawlins, D N Bateman. Clinical pharmacology of prochlorperazine in healthy young males. British journal of clinical pharmacology. 1991 Dec; 32(6):677-84. doi: . [PMID: 1768559]
I N Olver, L K Webster, J F Bishop, J Clarke, B L Hillcoat. A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy. European journal of cancer & clinical oncology. 1989 Oct; 25(10):1457-61. doi: 10.1016/0277-5379(89)90104-1. [PMID: 2591437]
R A Kramer. Protection against cisplatin nephrotoxicity by prochlorperazine. Cancer chemotherapy and pharmacology. 1989; 25(3):156-60. doi: 10.1007/bf00689575. [PMID: 2598405]
W B Taylor, D N Bateman. Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. British journal of clinical pharmacology. 1987 Feb; 23(2):137-42. doi: 10.1111/j.1365-2125.1987.tb03021.x. [PMID: 3828192]
A Fowler, W Taylor, D N Bateman. Plasma prochlorperazine assay by high-performance liquid chromatography--electrochemistry. Journal of chromatography. 1986 Jul; 380(1):202-5. doi: 10.1016/s0378-4347(00)83644-0. [PMID: 3745386]
T Pullar, J A Hunter, H A Capell. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. British journal of rheumatology. 1985 Aug; 24(3):269-76. doi: 10.1093/rheumatology/24.3.269. [PMID: 2861876]
D R Blake, P Winyard, J Lunec, A Williams, P A Good, S J Crewes, J M Gutteridge, D Rowley, B Halliwell, A Cornish. Cerebral and ocular toxicity induced by desferrioxamine. The Quarterly journal of medicine. 1985 Jul; 56(219):345-55. doi: 10.1093/oxfordjournals.qjmed.a067880. [PMID: 4095247]
S Mac Neil, S W Walker, H J Senior, S S Bleehen, S Tomlinson. Effects of extracellular calmodulin and calmodulin antagonists on B16 melanoma cell growth. The Journal of investigative dermatology. 1984 Jul; 83(1):15-9. doi: 10.1111/1523-1747.ep12261637. [PMID: 6736671]
J K Cooper, G McKay, K K Midha. Subnanogram quantitation of chlorpromazine in plasma by high-performance liquid chromatography with electrochemical detection. Journal of pharmaceutical sciences. 1983 Nov; 72(11):1259-62. doi: 10.1002/jps.2600721106. [PMID: 6644586]
K K Midha, E M Hawes, G Rauw, J McVittie, G McKay, J K Cooper, H U Shetty. Radioimmunoassay for prochlorperazine in human plasma. Therapeutic drug monitoring. 1983; 5(1):117-21. doi: 10.1097/00007691-198303000-00013. [PMID: 6845394]
G McKay, J K Cooper, K K Midha, K Hall, E M Hawes. Simple and sensitive high-performance liquid chromatographic procedure with electrochemical detection for the determination of plasma concentrations of trimeprazine following single oral doses. Journal of chromatography. 1982 Dec; 233(?):417-22. doi: 10.1016/s0378-4347(00)81778-8. [PMID: 7161357]
S D Harrison, J L Cox, R C Giles. Effects of prochlorperazine on experimental nephrotoxicity. Cancer chemotherapy and pharmacology. 1982 Dec; 10(1):62-7. doi: 10.1007/bf00257241. [PMID: 6218930]
M G Sankey, J E Holt, C M Kaye. A simple and sensitive H.P.L.C. method for the assay of prochlorperazine in plasma. British journal of clinical pharmacology. 1982 Apr; 13(4):578-80. doi: 10.1111/j.1365-2125.1982.tb01427.x. [PMID: 7066176]
W A Brown, T P Laughren. Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry research. 1981 Dec; 5(3):317-22. doi: 10.1016/0165-1781(81)90078-0. [PMID: 6119716]
S H Unger, G H Chiang. Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity. Journal of medicinal chemistry. 1981 Mar; 24(3):262-70. doi: 10.1021/jm00135a006. [PMID: 6167716]
G Langer, E J Sachar, F S Halpern. Effect of dopamine and neuroleptics on plasma growth hormone and prolactin in normal men. Psychoneuroendocrinology. 1978 Apr; 3(2):165-9. doi: 10.1016/0306-4530(78)90004-5. [PMID: 704750]
A Hulshoff, J H Perrin. Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives. Journal of medicinal chemistry. 1977 Mar; 20(3):430-9. doi: 10.1021/jm00213a022. [PMID: 576620]
I Jahns, U Breyer. The rat brain as a 'deep compartment' in the kinetics of a common metabolite of prochlorperazine and perphenazine. Drug metabolism and disposition: the biological fate of chemicals. 1976 Nov; 4(6):522-9. doi: NULL. [PMID: 11973]
D A Bender. Changes in serum tryptophan, tryptophan binding to serum albumin and serum total amino acid concentration after administration of neuroleptic drugs to rats. Biochemical Society transactions. 1976; 4(1):98-100. doi: 10.1042/bst0040098. [PMID: 1001641]
N H Lauersen, K H Wilson. Induction of midtrimester abortion by serial intravaginal administration of 15(S)-15-methyl-prostaglandin F2alpha (THAM) suppositories. Prostaglandins. 1975 Dec; 10(6):1037-45. doi: 10.1016/s0090-6980(75)80051-7. [PMID: 1208882]
H J Gaertner, G Liomin, D Villumsen, R Bertele, U Breyer. Tissue metabolites of trifluorperazine, fluphenazine, prochlorperazine, and perphenazine. Kinetics in chronic treatment. Drug metabolism and disposition: the biological fate of chemicals. 1975 Nov; 3(6):437-44. doi: . [PMID: 1218]
U Breyer, A Prox, R Bertele, H J Gaertner. Tissue metabolites of trifluoperazine, fluphenazine, prochlorperazine, and perphenazine in the rat: indentification and synthesis. Journal of pharmaceutical sciences. 1974 Dec; 63(12):1842-8. doi: 10.1002/jps.2600631204. [PMID: 4449013]
R M Hill, W M Verniaud, M G Horning, L B McCulley, N F Morgan. Infants exposed in utero to antiepileptic drugs. A prospective study. American journal of diseases of children (1960). 1974 May; 127(5):645-53. doi: 10.1001/archpedi.1974.02110240031002. [PMID: 4825584]
H Hinterberger, D E Wilcken. The effect of prolonged glucagon infusions on the urinary excretion of catecholamines and 4-hydroxy-3-methoxymandelic acid and on adrenal medullary tissue levels of catecholamines in patients with severe cardiac disease. Clinica chimica acta; international journal of clinical chemistry. 1974 Apr; 52(2):153-61. doi: 10.1016/0009-8981(74)90205-8. [PMID: 4828228]
H J Gaertner, U Breyer, G Liomin. Metabolism of trifluoperazine, fluphenazine, prochlorperazine and perphenazine in rats: in vitro and urinary metabolites. Biochemical pharmacology. 1974 Jan; 23(2):303-11. doi: 10.1016/0006-2952(74)90421-3. [PMID: 4813347]
U Breyer, H J Gaertner, A Prox. Formation of identical metabolites from piperazine- and dimethylamino-substituted phenothiazine drugs in man, rat and dog. Biochemical pharmacology. 1974 Jan; 23(2):313-22. doi: 10.1016/0006-2952(74)90422-5. [PMID: 4813348]
I S Forrest, J Fox, D E Green, A P Melikian, M T Serra. Total excretion of 3H-chlorpromazine and 3H-prochlorperazine in chronically dosed animals: balance sheet. Advances in biochemical psychopharmacology. 1974; 9(0):347-56. doi: NULL. [PMID: 4836211]
U Breyer, H J Gaertner. Tissue accumulation of metabolites during chronic administration of piperazine-substituted phenothiazine drugs. Advances in biochemical psychopharmacology. 1974; 9(0):167-73. doi: NULL. [PMID: 4151761]
R A Mueller, J I Fishburne, W E Brenner, J T Braaksma, L G Staurovsky, J L Hoffer, C H Hendricks. Changes in human plasma catecholamines and dopamine-beta-hydroxylase produced by prostaglandin F2 alpha. Prostaglandins. 1972 Sep; 2(3):219-26. doi: 10.1016/s0090-6980(72)80027-3. [PMID: 4653736]
A I Csapo, A Kivikoski, W G Wiest. Massive initial prostaglandin impact in postconceptional therapy. Prostaglandins. 1972 Aug; 2(2):125-34. doi: 10.1016/0090-6980(72)90046-9. [PMID: 4653230]
L A Hadwiger, A R Martin. Induced formation of phenylalanine ammonia lyase and pisatin by chlorpromazine and other phenothiazine derivatives. Biochemical pharmacology. 1971 Dec; 20(12):3255-61. doi: 10.1016/0006-2952(71)90430-8. [PMID: 5167294]
J M Willoughby, J Beckett, P J Kumar, A M Dawson. Controlled trial of azathioprine in Crohn's disease. Lancet (London, England). 1971 Oct; 2(7731):944-7. doi: 10.1016/s0140-6736(71)90268-6. [PMID: 4107900]
J E Wallace, J D Biggs. Determination of phenothiazine compounds in biologic specimens by UV spectrophotometry. Journal of pharmaceutical sciences. 1971 Sep; 60(9):1346-50. doi: 10.1002/jps.2600600912. [PMID: 4398099]
C G Rogers. Fatty acids of liver mitochondrial and microsomal lipids in the rat exposed to phenothiazine derivatives. Biochemical pharmacology. 1971 Sep; 20(9):2518-22. doi: 10.1016/0006-2952(71)90256-5. [PMID: 5163159]
M Uchida, Y Sugiura, Y Aoki, T Sugano. [Interference by drugs in the determination of urinary 17-hydroxycorticosteroid (17-OHCS) inhibition of color reaction in Porter-Silber reaction]. Rinsho byori. The Japanese journal of clinical pathology. 1971 Aug; 19(?):Suppl:209-10. doi: NULL. [PMID: 5167925]
Y Stephan, L Welin, F Mainard. [Binding to human serum proteins of drugs belonging to phenothiazine series, iminodibenzyle, thioxanthene and thiophenylpyridylamine]. Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles. 1971 Mar; 272(10):1451-4. doi: NULL. [PMID: 4994988]
J Wolff, A B Jones. Inhibition of hormone-sensitive adenyl cyclase by phenothiazines. Proceedings of the National Academy of Sciences of the United States of America. 1970 Feb; 65(2):454-9. doi: 10.1073/pnas.65.2.454. [PMID: 4313200]
M T Moore, M H Book. Sudden death in phenothiazine therapy. (A clinicopathologic study of 12 cases). The Psychiatric quarterly. 1970; 44(3):389-402. doi: 10.1007/bf01562983. [PMID: 5514886]
P Haux, S Natelson. A practical method for the assay of phenothiazines in biologic fluids. American journal of clinical pathology. 1970 Jan; 53(1):77-83. doi: 10.1093/ajcp/53.1.77. [PMID: 5460616]
S M Glick. Normal and abnormal secretion of growth hormone. Annals of the New York Academy of Sciences. 1968 Feb; 148(2):471-87. doi: 10.1111/j.1749-6632.1968.tb20370.x. [PMID: 4967798]
L Roizin, M A Kaufman, G Gold, V K Iyengar, J C Liu, S Keoseian. A multidisciplinary investigation of the phenothiazines. Mental hygiene. 1966 Oct; 50(4):574-9. doi: NULL. [PMID: 4961399]
E J VANLOON, T L FLANAGAN, W J NOVICK, A R MAASS. HEPATIC SECRETION AND URINARY EXCRETION OF THREE S35-LABELED PHENOTHIAZINES IN THE DOG. Journal of pharmaceutical sciences. 1964 Oct; 53(?):1211-3. doi: 10.1002/jps.2600531018. [PMID: 14249440]
B M PHILLIPS, T S MIYA. DISPOSITION OF S35-PROCHLORPERAZINE IN THE RAT. Journal of pharmaceutical sciences. 1964 Sep; 53(?):1098-101. doi: 10.1002/jps.2600530925. [PMID: 14234903]
R H MORRIS, P VASSALLI, F K BELLER, R T MCCLUSKEY. IMMUNOFLUORESCENT STUDIES OF RENAL BIOPSIES IN THE DIAGNOSIS OF TOXEMIA OF PREGNANCY. Obstetrics and gynecology. 1964 Jul; 24(?):32-46. doi: NULL. [PMID: 14211033]